IP Library Granted Patent US 8,961,930
Granted Patent B2
US 8,961,930 · App. 13/062,064 · Granted Feb 24, 2015

Isatin derivatives for use as in vivo imaging agents

Inventors: Eric Ofori Aboagye (Middlesex, GB); Graham Smith (London, GB); Quang-De Nguyen (London, GB); Erik Arstad (London, GB); Matthias Eberhard Glaser (London, GB)
Assignees: Imperial Innovations Limited; Hammersmith Imanet Limited
C07D403/12C07D403/14C07D405/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,961,930
App. No.
13/062,064
Granted
Feb 24, 2015
Kind
B2
Abstract

Isatin 5-sulfonamide derivatives, pharmaceutical compositions comprising the derivatives, their use as molecular imaging agents, their use for the diagnosis or treatment of diseases or disorders associated with dysregulation of apoptosis, methods for synthesizing the derivatives, methods for the molecular imaging of caspase activity and apoptosis, and methods of assessing the therapeutic effect of a test substance on caspase activity are disclosed.

Claims (31)

1. A compound of formula A:

or a salt or hydrate thereof, wherein

R is 3-fluorophenyl, 2,4-difluorophenyl, 3,5-difluorophenyl, an optionally substituted tetrahydropyran, an optionally substituted diazine or an optionally substituted triazole;

R′ is an optionally substituted phenyl or an optionally substituted triazole; and

wherein R and R′ are chosen such that when R′ is an optionally substituted phenyl, R is an optionally substituted triazole.

2. The compound of claim 1 , wherein the optionally substituted triazole is substituted with a substituted alkyl group.

3. The compound of claim 1 , wherein R and R′ are defined as follows:

Com-

pound

No.

R

R′

6

7

8

9

11

29

30

31

12

32

33

34

4. The compound of claim 1 , additionally comprising an imaging moiety.

5. The compound of claim 4 , wherein the imaging moiety is 18 F.

6. A pharmaceutical composition comprising the compound of claim 1 , and optionally one or more additional active ingredients, pharmaceutically acceptable excipients, carriers or diluents.

7. A compound of formula A:

or a salt, hydrate or prodrug thereof,

wherein R is selected from the group consisting of 3-fluorophenyl, 2,4-difluorophenyl and 3,5-difluorophenyl; and wherein R′ is a 2-fluoroethyl-substituted triazole.

8. A compound of formula [ 18 F]11:

Assignments (3)
CHANGE OF NAME Recorded Jul 8, 2020
From: IMPERIAL WHITE CITY INCUBATOR LIMITED
To: IMPERIAL COLLEGE INNOVATIONS LIMITED
Reel/Frame 053156/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2020
From: IMPERIAL INNOVATIONS LIMITED
To: IMPERIAL WHITE CITY INCUBATOR LIMITED
Reel/Frame 053335/0072 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2011
From: ABOAGYE, ERIC OFORI; SMITH, GRAHAM; NGUYEN, QUANG-DE; ARSTAD, ERIK; GLASER, MATTHIAS EBERHARD
To: IMPERIAL INNOVATIONS LIMITED; HAMMERSMITH IMANET LIMITED
Reel/Frame 027011/0656 →
Priority Claims (2)
GB 0816294.3 · Sep 5, 2008 · national
GB 0818076.2 · Oct 2, 2008 · national
Continuity (1)
Related Publication 20110195024A1 · Aug 11, 2011